Mammalian Cell Bioprocessing
Our research focusses on mammalian/human cell-based bioprocessing for bioproduction of therapeutical biologics. These include glycoproteins, such as monoclonal antibodies, viral vectors and cells. Development of production systems for Advanced Therapy Medical Products (ATMP), such as viral vectors and human stem cells, greatly benefits from our experience in the more mature glycoprotein field.
Intensification at very high cell density by continuous perfusion cultures is an important focus of the research, including record high cell densities for Chinese Hamster Ovary (CHO) cells. The sustainability advantages of intensified, more flexible and possibly smaller processes and equipment align as well towards major savings in terms of capital expenditure (CAPEX). These improved processes can also provide biological drugs and therapies for numerous currently unmet health needs enabling treatment for rare diseases and thereby contributing to improved equality. They can also decrease the costs and potentially lead-time for biosimilars or for new treatments against emerging health threats.
Our activities in bioprocessing include new avenues for development of high cell density perfusion cultures, modelling of processes, i.e. kinetic models of metabolism and of antibody glycosylation, cell- and process characterization based on omics information, new tools for on-line analysis, process analytical technology and purification process.
Veronique Chotteau is Director of AdBIOPRO, Vinnova Centre for Advanced Bioproduction by Continuous Processing, a collaboration of seven groups of KTH, Lund University, the Karolinska Centre for Cell Therapy KCC at Karolinska Hospital, Karolinska Institutet and Linköping University and an extensive platform of 15 industrial partners.
Research Team
